ID   SYT1_RAT                Reviewed;         421 AA.
AC   P21707; Q3S2E6; Q707P5;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 3.
DT   24-JUL-2024, entry version 225.
DE   RecName: Full=Synaptotagmin-1 {ECO:0000303|PubMed:25705886};
DE   AltName: Full=Synaptotagmin I {ECO:0000303|PubMed:11931641};
DE            Short=SytI;
DE   AltName: Full=p65 {ECO:0000303|PubMed:1985919};
GN   Name=Syt1 {ECO:0000312|RGD:3803};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=2333096; DOI=10.1038/345260a0;
RA   Perin M.S., Fried V.A., Mignery G.A., Jahn R., Suedhof T.C.;
RT   "Phospholipid binding by a synaptic vesicle protein homologous to the
RT   regulatory region of protein kinase C.";
RL   Nature 345:260-263(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=15238157; DOI=10.1186/1471-2164-5-43;
RA   Craxton M.A.;
RT   "Synaptotagmin gene content of the sequenced genomes.";
RL   BMC Genomics 5:43-43(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Wistar;
RA   Sunitha S.S., Thekkuveettil A.;
RT   "Functional analysis of synaptotagmin.";
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   PROTEIN SEQUENCE OF 214-233; 289-297; 355-366 AND 376-388, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus;
RA   Lubec G., Chen W.-Q.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   PROTEIN SEQUENCE OF 201-213 AND 333-352, FUNCTION AS C.BOTULINUM NEUROTOXIN
RP   TYPE B RECEPTOR (MICROBIAL INFECTION), AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=8144634; DOI=10.1016/s0021-9258(17)34087-5;
RA   Nishiki T., Kamata Y., Nemoto Y., Omori A., Ito T., Takahashi M.,
RA   Kozaki S.;
RT   "Identification of protein receptor for Clostridium botulinum type B
RT   neurotoxin in rat brain synaptosomes.";
RL   J. Biol. Chem. 269:10498-10503(1994).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=1985919; DOI=10.1016/s0021-9258(18)52480-7;
RA   Perin M.S., Brose N., Jahn R., Suedhof T.C.;
RT   "Domain structure of synaptotagmin (p65).";
RL   J. Biol. Chem. 266:623-629(1991).
RN   [7]
RP   INTERACTION WITH SV2A, AND DOMAIN.
RX   PubMed=8910372; DOI=10.1074/jbc.271.44.27770;
RA   Schivell A.E., Batchelor R.H., Bajjalieh S.M.;
RT   "Isoform-specific, calcium-regulated interaction of the synaptic vesicle
RT   proteins SV2 and synaptotagmin.";
RL   J. Biol. Chem. 271:27770-27775(1996).
RN   [8]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SYT2.
RX   PubMed=9867811; DOI=10.1074/jbc.274.1.59;
RA   Osborne S.L., Herreros J., Bastiaens P.I., Schiavo G.;
RT   "Calcium-dependent oligomerization of synaptotagmins I and II.
RT   Synaptotagmins I and II are localized on the same synaptic vesicle and
RT   heterodimerize in the presence of calcium.";
RL   J. Biol. Chem. 274:59-66(1999).
RN   [9]
RP   INTERACTION WITH RIMS1.
RC   TISSUE=Brain;
RX   PubMed=11438518; DOI=10.1074/jbc.m100929200;
RA   Coppola T., Magnin-Luethi S., Perret-Menoud V., Gattesco S., Schiavo G.,
RA   Regazzi R.;
RT   "Direct interaction of the Rab3 effector RIM with Ca2+ channels, SNAP-25,
RT   and synaptotagmin.";
RL   J. Biol. Chem. 276:32756-32762(2001).
RN   [10]
RP   INTERACTION WITH DNAJC5.
RX   PubMed=11931641; DOI=10.1042/bj20020123;
RA   Evans G.J., Morgan A.;
RT   "Phosphorylation-dependent interaction of the synaptic vesicle proteins
RT   cysteine string protein and synaptotagmin I.";
RL   Biochem. J. 364:343-347(2002).
RN   [11]
RP   COFACTOR, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF ARG-233.
RX   PubMed=11823420; DOI=10.1093/emboj/21.3.270;
RA   Sugita S., Shin O.H., Han W., Lao Y., Suedhof T.C.;
RT   "Synaptotagmins form a hierarchy of exocytotic Ca(2+) sensors with distinct
RT   Ca(2+) affinities.";
RL   EMBO J. 21:270-280(2002).
RN   [12]
RP   PALMITOYLATION AT CYS-74; CYS-75; CYS-77; CYS-79 AND CYS-82.
RX   PubMed=12782290; DOI=10.1016/s0014-5793(03)00449-6;
RA   Heindel U., Schmidt M.F., Veit M.;
RT   "Palmitoylation sites and processing of synaptotagmin I, the putative
RT   calcium sensor for neurosecretion.";
RL   FEBS Lett. 544:57-62(2003).
RN   [13]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE B RECEPTOR (MICROBIAL INFECTION),
RP   AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=14504267; DOI=10.1083/jcb.200305098;
RA   Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A.,
RA   Chapman E.R.;
RT   "Synaptotagmins I and II mediate entry of botulinum neurotoxin B into
RT   cells.";
RL   J. Cell Biol. 162:1293-1303(2003).
RN   [14]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE G RECEPTOR (MICROBIAL INFECTION),
RP   AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=15123599; DOI=10.1074/jbc.m403945200;
RA   Rummel A., Karnath T., Henke T., Bigalke H., Binz T.;
RT   "Synaptotagmins I and II act as nerve cell receptors for botulinum
RT   neurotoxin G.";
RL   J. Biol. Chem. 279:30865-30870(2004).
RN   [15]
RP   INTERACTION WITH SV2A; SV2B AND SV2C.
RX   PubMed=15866046; DOI=10.1016/j.mcn.2004.12.011;
RA   Schivell A.E., Mochida S., Kensel-Hammes P., Custer K.L., Bajjalieh S.M.;
RT   "SV2A and SV2C contain a unique synaptotagmin-binding site.";
RL   Mol. Cell. Neurosci. 29:56-64(2005).
RN   [16]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE B RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND MUTAGENESIS OF 47-MET--LEU-50; MET-47
RP   AND LEU-50.
RX   PubMed=17167421; DOI=10.1038/nature05387;
RA   Jin R., Rummel A., Binz T., Brunger A.T.;
RT   "Botulinum neurotoxin B recognizes its protein receptor with high affinity
RT   and specificity.";
RL   Nature 444:1092-1095(2006).
RN   [17]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE B RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND MUTAGENESIS OF 50-LEU-ASN-51.
RX   PubMed=17167418; DOI=10.1038/nature05411;
RA   Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R.,
RA   Stevens R.C.;
RT   "Structural basis of cell surface receptor recognition by botulinum
RT   neurotoxin B.";
RL   Nature 444:1096-1100(2006).
RN   [18]
RP   INTERACTION WITH SYT12, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   GLYCOSYLATION.
RX   PubMed=17190793; DOI=10.1083/jcb.200607021;
RA   Maximov A., Shin O.H., Liu X., Suedhof T.C.;
RT   "Synaptotagmin-12, a synaptic vesicle phosphoprotein that modulates
RT   spontaneous neurotransmitter release.";
RL   J. Cell Biol. 176:113-124(2007).
RN   [19]
RP   SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=20219474; DOI=10.1016/j.jmb.2010.02.041;
RA   Stenmark P., Dong M., Dupuy J., Chapman E.R., Stevens R.C.;
RT   "Crystal structure of the botulinum neurotoxin type G binding domain:
RT   insight into cell surface binding.";
RL   J. Mol. Biol. 397:1287-1297(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-128; SER-342 AND SER-344, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 132-266.
RX   PubMed=7697723; DOI=10.1016/0092-8674(95)90296-1;
RA   Sutton R.B., Davletov B.A., Berghuis A.M., Suedhof T.C., Sprang S.R.;
RT   "Structure of the first C2 domain of synaptotagmin I: a novel
RT   Ca2+/phospholipid-binding fold.";
RL   Cell 80:929-938(1995).
RN   [22]
RP   STRUCTURE BY NMR OF 140-267 IN COMPLEX WITH CALCIUM.
RX   PubMed=9819203; DOI=10.1021/bi981789h;
RA   Shao X., Fernandez I., Suedhof T.C., Rizo J.;
RT   "Solution structures of the Ca2+-free and Ca2+-bound C2A domain of
RT   synaptotagmin I: does Ca2+ induce a conformational change?";
RL   Biochemistry 37:16106-16115(1998).
RN   [23]
RP   STRUCTURE BY NMR OF 270-421.
RX   PubMed=11754837; DOI=10.1016/s0896-6273(01)00548-7;
RA   Fernandez I., Arac D., Ubach J., Gerber S.H., Shin O., Gao Y.,
RA   Anderson R.G., Suedhof T.C., Rizo J.;
RT   "Three-dimensional structure of the synaptotagmin 1 C2B-domain:
RT   synaptotagmin 1 as a phospholipid binding machine.";
RL   Neuron 32:1057-1069(2001).
RN   [24]
RP   INTERACTION WITH DNM1.
RX   PubMed=25964652; DOI=10.1242/jcs.161505;
RA   McAdam R.L., Varga K.T., Jiang Z., Young F.B., Blandford V.,
RA   McPherson P.S., Gong L.W., Sossin W.S.;
RT   "The juxtamembrane region of synaptotagmin 1 interacts with dynamin 1 and
RT   regulates vesicle fission during compensatory endocytosis in endocrine
RT   cells.";
RL   J. Cell Sci. 128:2229-2235(2015).
RN   [25]
RP   MUTAGENESIS OF ILE-367.
RX   PubMed=25705886; DOI=10.1172/jci79765;
RA   Baker K., Gordon S.L., Grozeva D., van Kogelenberg M., Roberts N.Y.,
RA   Pike M., Blair E., Hurles M.E., Chong W.K., Baldeweg T., Kurian M.A.,
RA   Boyd S.G., Cousin M.A., Raymond F.L.;
RT   "Identification of a human synaptotagmin-1 mutation that perturbs synaptic
RT   vesicle cycling.";
RL   J. Clin. Invest. 125:1670-1678(2015).
RN   [26]
RP   INTERACTION WITH RAB3A.
RX   PubMed=28057568; DOI=10.1016/j.ijbiomac.2016.12.074;
RA   Tang X., Xie C., Wang Y., Wang X.;
RT   "Localization of Rab3A-binding site on C2A domain of synaptotagmin I to
RT   reveal its regulatory mechanism.";
RL   Int. J. Biol. Macromol. 96:736-742(2017).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF MET-302; ASP-303; ASP-365; ILE-367 AND
RP   ASN-370.
RX   PubMed=30107533; DOI=10.1093/brain/awy209;
RG   Broad Center for Mendelian Genomics;
RA   Baker K., Gordon S.L., Melland H., Bumbak F., Scott D.J., Jiang T.J.,
RA   Owen D., Turner B.J., Boyd S.G., Rossi M., Al-Raqad M., Elpeleg O.,
RA   Peck D., Mancini G.M.S., Wilke M., Zollino M., Marangi G., Weigand H.,
RA   Borggraefe I., Haack T., Stark Z., Sadedin S., Tan T.Y., Jiang Y.,
RA   Gibbs R.A., Ellingwood S., Amaral M., Kelley W., Kurian M.A., Cousin M.A.,
RA   Raymond F.L.;
RT   "SYT1-associated neurodevelopmental disorder: a case series.";
RL   Brain 141:2576-2591(2018).
CC   -!- FUNCTION: Calcium sensor that participates in triggering
CC       neurotransmitter release at the synapse (PubMed:2333096,
CC       PubMed:30107533). May have a regulatory role in the membrane
CC       interactions during trafficking of synaptic vesicles at the active zone
CC       of the synapse. It binds acidic phospholipids with a specificity that
CC       requires the presence of both an acidic head group and a diacyl
CC       backbone. A Ca(2+)-dependent interaction between synaptotagmin and
CC       putative receptors for activated protein kinase C has also been
CC       reported. It can bind to at least three additional proteins in a
CC       Ca(2+)-independent manner; these are neurexins, syntaxin and AP2. Plays
CC       a role in dendrite formation by melanocytes.
CC       {ECO:0000250|UniProtKB:P21579, ECO:0000269|PubMed:2333096,
CC       ECO:0000269|PubMed:30107533}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type B (BoNT/B, botB); interaction is improved in the presence of
CC       gangliosides (PubMed:14504267, PubMed:17167418, PubMed:8144634). BoNT/B
CC       toxin binds to the membrane proximal vesicular domain of Syt1 (residues
CC       32-51) (PubMed:14504267, PubMed:17167421).
CC       {ECO:0000269|PubMed:14504267, ECO:0000269|PubMed:17167418,
CC       ECO:0000269|PubMed:17167421, ECO:0000269|PubMed:8144634}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type G (BoNT/G, botG); unlike the case with BoNT/B, interaction is not
CC       improved in the presence of gangliosides (PubMed:15123599,
CC       PubMed:20219474). BoNT/G toxin binds to the vesicular domain of Syt1
CC       (residues 32-53) (PubMed:15123599, PubMed:20219474).
CC       {ECO:0000269|PubMed:15123599, ECO:0000269|PubMed:20219474}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00041,
CC         ECO:0000269|PubMed:11823420, ECO:0000269|PubMed:9819203};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domains. {ECO:0000269|PubMed:9819203};
CC   -!- SUBUNIT: Homotetramer (Probable). Heterodimer; heterodimerizes with
CC       SYT2 in presence of calcium (PubMed:9867811). Interacts with SCAMP5 (By
CC       similarity). Interacts with STON2 (By similarity). Forms a complex with
CC       SV2B, syntaxin 1 and SNAP25 (By similarity). Interacts with SV2A, SV2B
CC       and SV2C (PubMed:15866046, PubMed:8910372). Interacts with RIMS1
CC       (PubMed:11438518). Interacts with PRRT2 (By similarity). Interacts with
CC       DNAJC5 in a phosphorylation-dependent manner (PubMed:11931641).
CC       Interacts (via N-terminus) with RAB3A (PubMed:28057568). Interacts with
CC       SYT12 (PubMed:17190793). Interacts with calmodulin (By similarity).
CC       Interacts with DNM1 (via C-terminal proline-rich domain (PRD)); this
CC       interaction facilitates vesicle fission during clathrin-mediated
CC       endocytosis (CME) (PubMed:25964652). {ECO:0000250|UniProtKB:P21579,
CC       ECO:0000250|UniProtKB:P46096, ECO:0000250|UniProtKB:P48018,
CC       ECO:0000269|PubMed:11438518, ECO:0000269|PubMed:11931641,
CC       ECO:0000269|PubMed:15866046, ECO:0000269|PubMed:17190793,
CC       ECO:0000269|PubMed:25964652, ECO:0000269|PubMed:28057568,
CC       ECO:0000269|PubMed:8910372, ECO:0000269|PubMed:9867811, ECO:0000305}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type B (BoNT/B, botB). Has lower affinity for BoNT/B than Syt2;
CC       mutating its residues to match those in Syt2 increases its affinity
CC       (PubMed:17167418, PubMed:17167421). {ECO:0000269|PubMed:14504267,
CC       ECO:0000269|PubMed:17167418, ECO:0000269|PubMed:17167421,
CC       ECO:0000269|PubMed:20219474, ECO:0000269|PubMed:8144634}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type G (BoNT/G, botG). {ECO:0000269|PubMed:15123599,
CC       ECO:0000269|PubMed:20219474}.
CC   -!- INTERACTION:
CC       P21707; P18484: Ap2a2; NbExp=5; IntAct=EBI-458098, EBI-539360;
CC       P21707; Q02294: Cacna1b; NbExp=2; IntAct=EBI-458098, EBI-540038;
CC       P21707; Q00954: Scn1b; NbExp=2; IntAct=EBI-458098, EBI-2619363;
CC       P21707; P04775: Scn2a; NbExp=2; IntAct=EBI-458098, EBI-2619448;
CC       P21707; P60881: Snap25; NbExp=24; IntAct=EBI-458098, EBI-1027214;
CC       P21707; Q02563: Sv2a; NbExp=2; IntAct=EBI-458098, EBI-466194;
CC       P21707; P21707: Syt1; NbExp=4; IntAct=EBI-458098, EBI-458098;
CC       P21707; P50232: Syt4; NbExp=3; IntAct=EBI-458098, EBI-540118;
CC       P21707; P63045: Vamp2; NbExp=7; IntAct=EBI-458098, EBI-520880;
CC       P21707; Q8WXE9: STON2; Xeno; NbExp=2; IntAct=EBI-458098, EBI-539742;
CC       P21707; O35526: Stx1a; Xeno; NbExp=3; IntAct=EBI-458098, EBI-400878;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle membrane
CC       {ECO:0000269|PubMed:11823420}; Single-pass membrane protein
CC       {ECO:0000255}. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle
CC       membrane {ECO:0000269|PubMed:17190793, ECO:0000269|PubMed:9867811};
CC       Single-pass membrane protein {ECO:0000255}. Cytoplasmic vesicle,
CC       secretory vesicle, chromaffin granule membrane
CC       {ECO:0000269|PubMed:1985919}; Single-pass membrane protein. Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain (at protein level)
CC       (PubMed:17190793). Predominantly expressed in rostral, phylogenetically
CC       younger brain regions, and in some endocrine tissues.
CC       {ECO:0000269|PubMed:17190793}.
CC   -!- DOMAIN: The first C2 domain mediates Ca(2+)-dependent phospholipid
CC       binding. {ECO:0000269|PubMed:11823420, ECO:0000269|PubMed:8910372}.
CC   -!- DOMAIN: The second C2 domain mediates interaction with SV2A and
CC       probably with STN2. {ECO:0000269|PubMed:8910372}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:17190793}.
CC   -!- SIMILARITY: Belongs to the synaptotagmin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52772; CAA36981.1; -; mRNA.
DR   EMBL; AJ617615; CAE85101.1; -; mRNA.
DR   EMBL; DQ181550; ABA00482.1; -; mRNA.
DR   PIR; S09595; S09595.
DR   RefSeq; NP_001028852.2; NM_001033680.2.
DR   RefSeq; XP_017450168.1; XM_017594679.1.
DR   PDB; 1BYN; NMR; -; A=140-267.
DR   PDB; 1K5W; NMR; -; A=270-421.
DR   PDB; 1RSY; X-ray; 1.90 A; A=132-266.
DR   PDB; 1TJM; X-ray; 1.18 A; A=271-421.
DR   PDB; 1TJX; X-ray; 1.04 A; A=271-421.
DR   PDB; 1UOV; X-ray; 1.65 A; A=271-421.
DR   PDB; 1UOW; X-ray; 1.04 A; A=271-421.
DR   PDB; 2YOA; X-ray; 1.50 A; A/B=271-421.
DR   PDB; 4WEE; X-ray; 0.89 A; A=140-266.
DR   PDB; 5CCG; X-ray; 3.50 A; E/F/K=141-421.
DR   PDB; 5CCH; X-ray; 3.60 A; E/F=141-421.
DR   PDB; 5CCI; X-ray; 4.10 A; E/F=141-421.
DR   PDB; 5CCJ; X-ray; 1.65 A; A/B/C/D=271-421.
DR   PDB; 5KJ7; X-ray; 3.50 A; E/F/K=141-419.
DR   PDB; 5KJ8; X-ray; 4.10 A; E/F/K=141-419.
DR   PDB; 5W5C; X-ray; 1.85 A; F=140-421.
DR   PDB; 5W5D; X-ray; 2.50 A; F=270-421.
DR   PDB; 6CXW; X-ray; 1.83 A; A=140-182, A=201-265.
DR   PDB; 6MTI; EM; 10.40 A; 1/6=141-267, 2/3/4/5=141-421.
DR   PDB; 8C5H; X-ray; 1.68 A; S=142-265.
DR   PDBsum; 1BYN; -.
DR   PDBsum; 1K5W; -.
DR   PDBsum; 1RSY; -.
DR   PDBsum; 1TJM; -.
DR   PDBsum; 1TJX; -.
DR   PDBsum; 1UOV; -.
DR   PDBsum; 1UOW; -.
DR   PDBsum; 2YOA; -.
DR   PDBsum; 4WEE; -.
DR   PDBsum; 5CCG; -.
DR   PDBsum; 5CCH; -.
DR   PDBsum; 5CCI; -.
DR   PDBsum; 5CCJ; -.
DR   PDBsum; 5KJ7; -.
DR   PDBsum; 5KJ8; -.
DR   PDBsum; 5W5C; -.
DR   PDBsum; 5W5D; -.
DR   PDBsum; 6CXW; -.
DR   PDBsum; 6MTI; -.
DR   PDBsum; 8C5H; -.
DR   AlphaFoldDB; P21707; -.
DR   SMR; P21707; -.
DR   BioGRID; 247745; 7.
DR   CORUM; P21707; -.
DR   DIP; DIP-29064N; -.
DR   IntAct; P21707; 26.
DR   MINT; P21707; -.
DR   STRING; 10116.ENSRNOP00000069194; -.
DR   GlyCosmos; P21707; 1 site, No reported glycans.
DR   GlyGen; P21707; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P21707; -.
DR   PhosphoSitePlus; P21707; -.
DR   SwissPalm; P21707; -.
DR   jPOST; P21707; -.
DR   PaxDb; 10116-ENSRNOP00000049624; -.
DR   Ensembl; ENSRNOT00000048880.3; ENSRNOP00000049624.2; ENSRNOG00000006426.7.
DR   Ensembl; ENSRNOT00055028911; ENSRNOP00055023267; ENSRNOG00055017023.
DR   Ensembl; ENSRNOT00060006122; ENSRNOP00060004535; ENSRNOG00060003698.
DR   Ensembl; ENSRNOT00065004587; ENSRNOP00065003286; ENSRNOG00065003237.
DR   GeneID; 25716; -.
DR   KEGG; rno:25716; -.
DR   UCSC; RGD:3803; rat.
DR   AGR; RGD:3803; -.
DR   CTD; 6857; -.
DR   RGD; 3803; Syt1.
DR   eggNOG; KOG1028; Eukaryota.
DR   GeneTree; ENSGT00940000155394; -.
DR   InParanoid; P21707; -.
DR   OMA; CLLGCNA; -.
DR   OrthoDB; 590187at2759; -.
DR   PhylomeDB; P21707; -.
DR   TreeFam; TF315600; -.
DR   Reactome; R-RNO-181429; Serotonin Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-210500; Glutamate Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-212676; Dopamine Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-264642; Acetylcholine Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-RNO-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-RNO-888590; GABA synthesis, release, reuptake and degradation.
DR   EvolutionaryTrace; P21707; -.
DR   PRO; PR:P21707; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000006426; Expressed in frontal cortex and 15 other cell types or tissues.
DR   GO; GO:0030424; C:axon; ISO:RGD.
DR   GO; GO:0042584; C:chromaffin granule membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0031045; C:dense core granule; IDA:MGI.
DR   GO; GO:0060076; C:excitatory synapse; IDA:BHF-UCL.
DR   GO; GO:0070382; C:exocytic vesicle; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:RGD.
DR   GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IDA:SynGO.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0044306; C:neuron projection terminus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0099524; C:postsynaptic cytosol; IDA:SynGO.
DR   GO; GO:0014069; C:postsynaptic density; IDA:SynGO.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:SynGO.
DR   GO; GO:0048786; C:presynaptic active zone; IDA:SynGO.
DR   GO; GO:0099523; C:presynaptic cytosol; IDA:SynGO.
DR   GO; GO:0042734; C:presynaptic membrane; ISO:RGD.
DR   GO; GO:0030141; C:secretory granule; IDA:RGD.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:SynGO.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IDA:SynGO.
DR   GO; GO:0043195; C:terminal bouton; HDA:ParkinsonsUK-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IDA:RGD.
DR   GO; GO:0061891; F:calcium ion sensor activity; ISO:RGD.
DR   GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IDA:RGD.
DR   GO; GO:0030276; F:clathrin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISO:RGD.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0000149; F:SNARE binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019905; F:syntaxin binding; IDA:BHF-UCL.
DR   GO; GO:0017075; F:syntaxin-1 binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030348; F:syntaxin-3 binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0048791; P:calcium ion-regulated exocytosis of neurotransmitter; ISO:RGD.
DR   GO; GO:0099502; P:calcium-dependent activation of synaptic vesicle fusion; ISO:RGD.
DR   GO; GO:0017156; P:calcium-ion regulated exocytosis; TAS:RGD.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0071277; P:cellular response to calcium ion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0005513; P:detection of calcium ion; IDA:RGD.
DR   GO; GO:0098746; P:fast, calcium ion-dependent exocytosis of neurotransmitter; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0007269; P:neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IDA:RGD.
DR   GO; GO:1903235; P:positive regulation of calcium ion-dependent exocytosis of neurotransmitter; ISS:UniProtKB.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; ISO:RGD.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; IMP:CACAO.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0031340; P:positive regulation of vesicle fusion; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051291; P:protein heterooligomerization; IPI:ARUK-UCL.
DR   GO; GO:0017158; P:regulation of calcium ion-dependent exocytosis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISO:RGD.
DR   GO; GO:1903305; P:regulation of regulated secretory pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; ISS:ParkinsonsUK-UCL.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:RGD.
DR   GO; GO:0061669; P:spontaneous neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; IBA:GO_Central.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; ISO:RGD.
DR   GO; GO:0071911; P:synchronous neurotransmitter secretion; ISO:RGD.
DR   GO; GO:0048278; P:vesicle docking; IDA:RGD.
DR   CDD; cd08385; C2A_Synaptotagmin-1-5-6-9-10; 1.
DR   CDD; cd08402; C2B_Synaptotagmin-1; 1.
DR   CDD; cd21963; Syt1_N; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR001565; Synaptotagmin.
DR   PANTHER; PTHR10024; SYNAPTOTAGMIN; 1.
DR   PANTHER; PTHR10024:SF239; SYNAPTOTAGMIN-1; 1.
DR   Pfam; PF00168; C2; 2.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00399; SYNAPTOTAGMN.
DR   SMART; SM00239; C2; 2.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 2.
DR   PROSITE; PS50004; C2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cytoplasm; Cytoplasmic vesicle; Differentiation;
KW   Direct protein sequencing; Glycoprotein; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Phosphoprotein; Reference proteome; Repeat;
KW   Synapse; Transmembrane; Transmembrane helix.
FT   CHAIN           1..421
FT                   /note="Synaptotagmin-1"
FT                   /id="PRO_0000183940"
FT   TOPO_DOM        1..57
FT                   /note="Vesicular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..79
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        80..421
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          141..260
FT                   /note="C2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          272..405
FT                   /note="C2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   REGION          112..141
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          135..381
FT                   /note="Phospholipid binding"
FT                   /evidence="ECO:0000305"
FT   BINDING         171
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         172
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         172
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         178
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         230
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         230
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         231
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         232
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         232
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         232
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         235
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         236
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         238
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         238
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         303
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         303
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         309
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         363
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         363
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         365
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         365
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         371
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   MOD_RES         128
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         229
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P46096"
FT   MOD_RES         264
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P46096"
FT   MOD_RES         342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   LIPID           74
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12782290"
FT   LIPID           75
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12782290"
FT   LIPID           77
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12782290"
FT   LIPID           79
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12782290"
FT   LIPID           82
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12782290"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   MUTAGEN         47..50
FT                   /note="MNEL->FNEI: Greatly increased binding of fragment 1-
FT                   53 to C.botulinum type B (BoNT/B, botB) heavy chain;
FT                   increases its resemblance to Syt2."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         47
FT                   /note="M->F: Slightly increased binding of fragment 1-53 to
FT                   BoNT/B heavy chain."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         50..51
FT                   /note="LH->IN: Binds to BoNT/B in the absence of
FT                   gangliosides."
FT                   /evidence="ECO:0000269|PubMed:17167418"
FT   MUTAGEN         50
FT                   /note="L->I: Increased binding of fragment 1-53 to BoNT/B
FT                   heavy chain."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         233
FT                   /note="R->Q: Impaired Ca(2+)-affinity."
FT                   /evidence="ECO:0000269|PubMed:11823420"
FT   MUTAGEN         302
FT                   /note="M->K: Fails to localize at nerve terminals."
FT                   /evidence="ECO:0000269|PubMed:30107533"
FT   MUTAGEN         303
FT                   /note="D->G: Fails to relocalize to nerve terminals after
FT                   stimulation of neurotransmitter release."
FT                   /evidence="ECO:0000269|PubMed:30107533"
FT   MUTAGEN         365
FT                   /note="D->E: Fails to relocalize to nerve terminals after
FT                   stimulation of neurotransmitter release."
FT                   /evidence="ECO:0000269|PubMed:30107533"
FT   MUTAGEN         367
FT                   /note="I->T: Slows synaptic vesicle fusion kinetics and
FT                   exocytosis. Impairs the kinetics of synaptic vesicle
FT                   endocytosis."
FT                   /evidence="ECO:0000269|PubMed:25705886,
FT                   ECO:0000269|PubMed:30107533"
FT   MUTAGEN         370
FT                   /note="N->K: Slows synaptic vesicle fusion kinetics and
FT                   exocytosis."
FT                   /evidence="ECO:0000269|PubMed:30107533"
FT   CONFLICT        188
FT                   /note="D -> E (in Ref. 1; CAA36981)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        374
FT                   /note="G -> D (in Ref. 1; CAA36981)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        393
FT                   /note="M -> I (in Ref. 1; CAA36981)"
FT                   /evidence="ECO:0000305"
FT   STRAND          144..152
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   TURN            153..156
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          157..166
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   HELIX           172..174
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          179..187
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:8C5H"
FT   STRAND          205..212
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   HELIX           216..219
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          223..230
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          238..246
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   HELIX           247..249
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          256..261
FT                   /evidence="ECO:0007829|PDB:4WEE"
FT   STRAND          275..283
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   TURN            284..287
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          288..298
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          302..306
FT                   /evidence="ECO:0007829|PDB:5W5D"
FT   STRAND          310..318
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          321..327
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          338..346
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   HELIX           349..354
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          356..363
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          366..368
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          371..379
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   HELIX           384..395
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   STRAND          396..399
FT                   /evidence="ECO:0007829|PDB:1K5W"
FT   STRAND          401..406
FT                   /evidence="ECO:0007829|PDB:1TJX"
FT   HELIX           410..417
FT                   /evidence="ECO:0007829|PDB:1TJX"
SQ   SEQUENCE   421 AA;  47399 MW;  06CE28F04C97A722 CRC64;
     MVSASHPEAL AAPVTTVATL VPHNATEPAS PGEGKEDAFS KLKQKFMNEL HKIPLPPWAL
     IAIAIVAVLL VVTCCFCVCK KCLFKKKNKK KGKEKGGKNA INMKDVKDLG KTMKDQALKD
     DDAETGLTDG EEKEEPKEEE KLGKLQYSLD YDFQNNQLLV GIIQAAELPA LDMGGTSDPY
     VKVFLLPDKK KKFETKVHRK TLNPVFNEQF TFKVPYSELG GKTLVMAVYD FDRFSKHDII
     GEFKVPMNTV DFGHVTEEWR DLQSAEKEEQ EKLGDICFSL RYVPTAGKLT VVILEAKNLK
     KMDVGGLSDP YVKIHLMQNG KRLKKKKTTI KKNTLNPYYN ESFSFEVPFE QIQKVQVVVT
     VLDYDKIGKN DAIGKVFVGY NSTGAELRHW SDMLANPRRP IAQWHTLQVE EEVDAMLAVK
     K
//
